Karyopharm Therapeutics Inc. (KPTI) Forecasted to Post Q3 2017 Earnings of ($0.63) Per Share

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – Wedbush boosted their Q3 2017 earnings per share (EPS) estimates for Karyopharm Therapeutics in a report released on Tuesday. Wedbush analyst D. Nierengarten now anticipates that the company will earn ($0.63) per share for the quarter, up from their previous forecast of ($0.64). Wedbush also issued estimates for Karyopharm Therapeutics’ FY2017 earnings at ($2.63) EPS, Q1 2018 earnings at ($0.66) EPS, Q2 2018 earnings at ($0.61) EPS, Q3 2018 earnings at ($0.61) EPS, Q4 2018 earnings at ($0.63) EPS, FY2018 earnings at ($2.50) EPS, FY2019 earnings at ($1.37) EPS, FY2020 earnings at $0.08 EPS and FY2021 earnings at $1.73 EPS.

A number of other brokerages also recently commented on KPTI. Cantor Fitzgerald restated an “overweight” rating and issued a $18.00 target price on shares of Karyopharm Therapeutics in a research note on Monday, May 15th. Jefferies Group LLC restated a “buy” rating and issued a $19.00 target price (up from $16.00) on shares of Karyopharm Therapeutics in a research note on Thursday. Zacks Investment Research downgraded shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. Canaccord Genuity set a $18.00 target price on shares of Karyopharm Therapeutics and gave the stock a “buy” rating in a research note on Tuesday. Finally, ValuEngine downgraded shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, May 25th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $14.56.

WARNING: This article was originally reported by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another site, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The legal version of this article can be read at https://www.com-unik.info/2017/08/12/karyopharm-therapeutics-inc-kpti-forecasted-to-post-q3-2017-earnings-of-0-63-per-share.html.

Shares of Karyopharm Therapeutics (KPTI) opened at 8.55 on Friday. Karyopharm Therapeutics has a 1-year low of $6.27 and a 1-year high of $14.63. The company has a 50 day moving average price of $9.11 and a 200 day moving average price of $10.01. The company’s market capitalization is $403.03 million.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Tuesday, August 8th. The company reported ($0.64) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.64). Karyopharm Therapeutics had a negative return on equity of 70.42% and a negative net margin of 67,267.47%. The firm’s revenue was down 95.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.84) EPS.

Several large investors have recently made changes to their positions in the company. Palo Alto Investors LLC boosted its stake in shares of Karyopharm Therapeutics by 6.4% in the first quarter. Palo Alto Investors LLC now owns 3,406,475 shares of the company’s stock valued at $43,739,000 after buying an additional 206,079 shares during the last quarter. Metropolitan Life Insurance Co. NY boosted its stake in shares of Karyopharm Therapeutics by 12.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 21,911 shares of the company’s stock valued at $206,000 after buying an additional 2,460 shares during the last quarter. State Street Corp boosted its stake in shares of Karyopharm Therapeutics by 6.6% in the fourth quarter. State Street Corp now owns 406,103 shares of the company’s stock valued at $3,820,000 after buying an additional 25,015 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Karyopharm Therapeutics by 0.9% in the first quarter. Wellington Management Group LLP now owns 5,780,553 shares of the company’s stock valued at $74,223,000 after buying an additional 54,137 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Karyopharm Therapeutics by 347.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 261,055 shares of the company’s stock valued at $2,454,000 after buying an additional 202,714 shares during the last quarter. 57.46% of the stock is owned by hedge funds and other institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Earnings History and Estimates for Karyopharm Therapeutics (NASDAQ:KPTI)

What are top analysts saying about Karyopharm Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Karyopharm Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit